tirzepatide patent expiry in india Eli Lilly boss reports progress after Novo's expiration India's generic semaglutide surge |

We believe a healthy community depends on everyone having access to quality independent journalism

family history, physical inactivity, high-risk ethnicity, poor diet, hypertension, dyslipidemia, PCOS, prior gestational diabetes, prediabetes, or cardiovascular disease All adults aged 45 or older, regardless of weight Children aged 10 or older with overweight or obesity and two or more risk factors, screened at puberty onset Pregnant individuals: gestational diabetes screening at 2428 weeks New in ADA 2026 Screen individuals initiating immune checkpoint inhibitors, PI3K inhibitors, mTOR inhibitors, or high-dose glucocorticoids, a significant new addition for oncology and transplant patients

Tirzepatide, sold as Mounjaro and Zepbound, was not separately classified in the 2022 data and was not yet approved for weight management at that time, meaning it is not reflected in these figures

Clear plans, visible progress For every body, every step 15,000+ Members Get access to a growing community, doctor-led plans and on-going peer support Of ReadyRx patients reported a positive change since starting a treatment *of reporting patients 2 Minutes It takes to complete our online assessment to see if youre eligible for treatment Real people, real outcomes Traditional healthcare can be frustrating So we built a platform that isnt

How long does it take to see results with Zepbound vs

No equilibration step was included before measurements